Guggenheim Maintains Buy on Soleno Therapeutics, Raises Price Target to $97

Benzinga · 05/08 14:26
Guggenheim analyst Debjit Chattopadhyay maintains Soleno Therapeutics (NASDAQ:SLNO) with a Buy and raises the price target from $81 to $97.